Novel anti-obesity effect of scutellarein and potential underlying mechanism of actions

被引:31
|
作者
Lin, Yiguang [1 ]
Ren, Nina [2 ]
Li, Siyu [3 ]
Chen, Ming [3 ]
Pu, Peng [3 ]
机构
[1] Univ Technol Sydney, Sch Life Sci, Broadway, NSW 2007, Australia
[2] Guangdong Second Prov Peoples Hosp, Guangdong Online Hosp, Guangzhou 510317, Guangdong, Peoples R China
[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing, Peoples R China
基金
中国国家自然科学基金;
关键词
Scutellarein; Obesity; Hyperlipidemia; Inflammation; Lipid metabolism; ACTIVATED PROTEIN-KINASE; CHOLESTEROL EFFLUX; INSULIN-RESISTANCE; LIPID HOMEOSTASIS; OBESITY; INFLAMMATION; MACROPHAGES; EXPRESSION; HORMONE; GLUCOSE;
D O I
10.1016/j.biopha.2019.109042
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Aims: Scutellarein (Sc), a natural compound and an active ingredient of Erigeron breviscapus (vant.), shows anti-inflammatory and antioxidant properties and has the potential for obesity treatment. However, no previous in vivo study has been conducted to assess the role of Sc in obesity. This study investigated the effects of Sc on obesity and associated hyperlipidemia and fatty liver and explores the underlying mechanisms of action in a mouse model. Methods: The study was conducted using a well-established mouse model of obesity induced by high-fat diet (HFD) feeding. Anti-obesity effects were assessed using body weight, abdominal circumference, white adipose tissue, adiposity index, and fatty liver index. Lipid lowering and liver protective effects were examined by blood sample analysis. Lipid dystopia deposition was confirmed by liver pathological sections. The signaling pathways of lipid metabolism and cytokine/inflammatory mediator were evaluated using Real-Time PCR and Western blot. Results: Central obesity, dyslipidemia, inflammation, and hepatic steatosis were developed in mice fed with HFD. Administration of Sc at a dose of 50 mg/kg for 16 weeks effectively attenuated all obesity indicators tested. Further studies revealed the antagonistic effect of Sc on hyperlipidemia was a result of the repression of the lipid synthesis pathway, de novo pathway, HMGCR, promoting fatty acid oxidation (PPAR alpha, CPT-1a) and increased cholesterol output (PPAR gamma-LXR alpha-ABCA1). The anti-inflammatory effect was attributed to blocking the expression of inflammatory genes, including TNF-alpha, IL-6, NF-kappa B. Conclusions: These results suggest that Sc possesses important novel anti-obesity effects accompanying lipid lowering and anti-inflammation-based liver protective effects. These favorable effects are causally associated with the suppression of gene expression of inflammatory cytokines and fine regulation of genes responsible for energy metabolism. Our results advance the understanding of the pharmacological actions of Sc, and provides a role for Sc in effective management of obesity.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Food Components with Anti-Obesity Effect
    Kim, Kee-Hong
    Park, Yeonhwa
    ANNUAL REVIEW OF FOOD SCIENCE AND TECHNOLOGY, VOL 2, 2011, 2 : 237 - 257
  • [22] Anti-obesity effect of diacylglycerol oil
    Meguro, Shinichi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 21P - 21P
  • [23] Anti-obesity actions of mastication driven by histamine neurons in rats
    Sakata, T
    Yoshimatsu, H
    Masaki, T
    Tsuda, K
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2003, 228 (10) : 1106 - 1110
  • [24] Moringa Leaf Extract Anti-obesity potential
    Pandey, Sunita S.
    Mishra, Ravi
    Ramesh, P.
    Mullasseri, Sileesh
    Sahoo, Nihar Ranjan
    Jadav, Ravindra
    Habeeb, Jasmin
    Unni, Anjana P.
    Verma, Sudhir
    Badrinarayan, S.
    CURRENT SCIENCE, 2019, 117 (03): : 352 - 353
  • [25] PERFLUOROOCTYL BROMIDE - POTENTIAL ANTI-OBESITY COMPOUND
    HUSSAIN, M
    NIAZI, S
    ARAMBULO, A
    LOND, DM
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1977, 66 (06) : 907 - 908
  • [26] A novel anti-obesity peptide that targets the hypothalamus
    Carty, Senegal
    NATURE REVIEWS ENDOCRINOLOGY, 2025, : 267 - 267
  • [27] The efficacy and safety of novel anti-obesity therapies
    Papazafiropoulou, A. K.
    Papanas, N.
    Melidonis, A.
    ARCHIVES OF HELLENIC MEDICINE, 2015, 32 (03): : 295 - 301
  • [28] Novel anti-obesity drugs and plasma lipids
    Nikolic, Dragana
    Toth, Peter P.
    Ferlita, Alessandra
    Di Bartolo, Vittoria
    Montalto, Giuseppe
    Banach, Maciej
    Rizzo, Manfredi
    CLINICAL LIPIDOLOGY, 2014, 9 (02) : 179 - 187
  • [29] Novel anti-obesity drugs for people with HIV
    Chandiwana, Nomathemba
    Manne-Goehler, Jennifer
    Calmy, Alexandra
    Gaayeb, Lobna
    Venter, Willem
    LANCET HIV, 2024, 11 (08): : e502 - e503
  • [30] Substance P as a novel anti-obesity target
    Karagiannides, Jordanes
    Espinoza, Daniel
    Torres, Daniel
    Tseng, Yu-hua
    Pothoulakis, Charalabos
    Kokkotou, Efi
    GASTROENTEROLOGY, 2007, 132 (04) : A542 - A542